Genome Therapeutics to Present at BIO 2003 Annual Convention.Business Editors/Health/Medical Writers BIO 2003 Annual Convention WALTHAM, Mass.--(BUSINESS WIRE)--June 18, 2003 Genome Therapeutics' (Nasdaq: GENE) Chairman and Chief Executive Officer, Steven M. Rauscher, will report on the progress of the Company's product development program through a presentation at the BIO 2003 Annual Convention on Wednesday, June 25, 2003 at 8:45 AM ET in Washington, DC. Hosted by the Biotechnology Industry Organization Biotechnology Industry Organization or BIO was founded 1993 in Washington, DC. James C. Greenwood is BIO's current President. External links
The presentation at the convention's Business Forum will be webcast live through the Company's website at www.genomecorp.com and will be archived for 90 days. More information about the conference and BIO is available at www.bio.org/events/2003/. About Genome Therapeutics Genome Therapeutics is a biopharmaceutical company focused on the discovery and development of pharmaceutical products for specialty markets. The Company's lead product candidate, Ramoplanin, is in development for the prevention, treatment and control of serious hospital-based infections. Ramoplanin is currently in a Phase III clinical trial Noun 1. phase III clinical trial - a large clinical trial of a treatment or drug that in phase I and phase II has been shown to be efficacious with tolerable side effects; after successful conclusion of these clinical trials it will receive formal approval from the for the prevention of bloodstream infections caused by vancomycin-resistant enterococci (VRE VRE vancomycin-resistant enterococcus. VRE Vancomycin-resistent enterococcus, see there ), and in a Phase II clinical trial Noun 1. phase II clinical trial - a clinical trial on more persons than in phase I; intended to evaluate the efficacy of a treatment for the condition it is intended to treat; possible side effects are monitored phase II for the treatment of Clostridium clostridium Any of the rod-shaped, usually gram-positive bacteria (see gram stain) that make up the genus Clostridium. They are found in soil, water, and the intestinal tracts of humans and other animals. Some species grow only in the complete absence of oxygen. difficile-associated diarrhea (CDAD CDAD Clostridium Difficile-Associated Diarrhea CDAD Component Data Administrator ). Genome Therapeutics' biopharmaceutical portfolio also includes seven major product discovery and development alliances with pharmaceutical companies including Amgen, AstraZeneca, bioMerieux, Schering-Plough and Wyeth. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion